News

Pimavanserin is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that may play a role in depression. Massachusetts General Hospital (MGH) Department of Psychiatry executive vice

Fast Track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions and address an unmet medical need. The designation enables

The partnership will identify and develop bicyclic peptides, Bicycles, a novel class of small molecule medicines designed to overcome several limitations of existing drug modalities. The deal tasks Bicycle with identifying bicyclic peptides

The collaboration integrates cognitive computing capabilities of IBM Watson with Pfizer’s scientific know how to help scientists generate meaningful insights. Pfizer will be the first company to use

The acquisition is expected to expand the UK based Heptares’ intellectual assets and platform for structure-based drug design and development centred on G protein-coupled receptors (GPCRs). Considered to

The Natrix Protein A platform is expected to pave the way for a new generation of more flexible, highly-productive single-use based biologics production facilities for both batch and

Risankizumab is being evaluated in immunological disorders, including Crohn's disease, psoriasis, psoriatic arthritis and asthma. Risankizumab is an investigational treatment that is part of a collaboration between Boehringer

Evotec announced the signing of a set of collaboration agreements with the life science business of Merck, which will combine Merck's portfolio of genome editing technologies with Evotec's versatile

PF-05280014 demonstrated equivalence in objective response rate to Herceptin after 25 weeks of treatment in first line patients with HER2-positive metastatic breast cancer. The Reflections B3271002 is a